tipapkinogene sovacivec

AXP000182.1 · Cancer vaccine

Platform
MVA
Originator
Transgene
Sponsor
Transgene

Names

NameTypeSource
tipapkinogene sovacivecpreferred namecurator
TG4001codencit
MVA-HPV-IL2synonymncit
MVA-HPV16E6/E7-IL2synonymncit
RG3484former codencit
RO5217790former codencit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA
Replication
non replicating
Modifications
HPV-16 E6, HPV-16 E7 and IL-2 cassettes inserted into MVA
Transgenes
HPV-16 E6, HPV-16 E7, IL2
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C88326
FDA UNII
P34L5Y2SR5

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03260023Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersActive not recruitingPhase 1/22017-09-012024-09-18143HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma
NCT01022346A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) InfectionCompletedPhase 22009-082013-09206Cervical Intraepithelial Neoplasia

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 37506588Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.European journal of cancer (Oxford, England : 1990)2023cited by trial NCT03260023
PMID 21284968Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy.American journal of obstetrics and gynecology2011name in title: TG4001

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41294662Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials.Current oncology (Toronto, Ont.)2025name in abstract: TG4001

Notes

TG4001: MVA encoding HPV-16 E6 and E7 plus human IL-2, for HPV16-positive cancers; phase 1b/2 and a randomised phase 2 with avelumab (missed its primary endpoint, reported 2024). Also carried the Roche codes RO5217790/R3484. E6/E7 are deleted/detoxified in some descriptions; modification detail not verified here.

How to cite

tipapkinogene sovacivec (AXP000182.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000182.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.